NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment

I-Mab's givastomig is a unique immune-boosting drug for stomach cancer, expected to outperform competitors, according to Leerink.

I-Mab's Givastomig: A Potential Game Changer for Stomach Cancer Treatment
Credit: I-Mab
Already have an account? Sign in.
10/03/2025 · 7:07 AM
IMAB
/ Don’t stop at just one post.

Related↓

US Considers Major Curbs on Chinese Medicines
09/10/2025 · 3:00 PM

US Considers Major Curbs on Chinese Medicines

US may curb Chinese drugs over national security fears, with stricter reviews for deals/data. I-Mab stock fell but is a US firm. China's biotech role is growing. White House denies active consideration of draft order.

/ Subscriber only
/ Read more

Feed↓

Enobosarm Grabs Novo Nordisk’s Attention: Veru’s Big Obesity Breakthrough
Featured/ 06/04/2026 · 1:15 PM

Enobosarm Grabs Novo Nordisk’s Attention: Veru’s Big Obesity Breakthrough

Veru partnered with Novo Nordisk to test enobosarm + Wegovy for fat loss while keeping muscle; stock surged.

/ Subscriber only
Amneal Wins FDA Approval for Ready-to-Use Romidepsin Injection – No Mixing Needed!
06/04/2026 · 12:56 PM

Amneal Wins FDA Approval for Ready-to-Use Romidepsin Injection – No Mixing Needed!

FDA approves Amneal ready-to-use romidepsin injection for rare skin cancer, simplifying use and giving 180-day exclusivity.

/ Subscriber only
Texas AG Ken Paxton Investigates Celsius & Alani Nu Over Dangerous Caffeine Levels in Drinks Marketed to Kids
06/04/2026 · 12:28 PM

Texas AG Ken Paxton Investigates Celsius & Alani Nu Over Dangerous Caffeine Levels in Drinks Marketed to Kids

Texas AG is investigating Celsius over high caffeine energy drinks linked to health risks in kids; company stock drops.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe